Takeda's Dengue Shot is 80% Effective in Phase III Trial

November 28, 2019

Takeda's Dengue Shot is 80% Effective in Phase III Trial

Takeda has released results from a clinical trial that found its dengue shot was 95.4% effective in preventing dengue that required hospitalization; there were five hospitalizations in the vaccine group versus 53 in the placebo group. The company will submit these phase III results for regulatory approval. With clinical trials taking place in more than 200 countries worldwide, Yourway is the partner that companies need to navigate the diverse and ever-changing global regulatory landscape.

Back to Index

Media

Upcoming Event

IQPC CTS

August 24-26, 2020
Brussels, Belgium

Schedule a Meeting

Media

Articles

The New Normal in Clinical Trial Protection

Open chat

Hello! How can I help you?